Meridian Bioscience (VIVO) 10-Q 7 May 21 2021 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Mar. 31, 2021	Apr. 30, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Entity Interactive Data Current	Yes
Document Transition Report	false
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Period End Date	Mar. 31, 2021
Document Fiscal Period Focus	Q2
Entity Registrant Name	MERIDIAN BIOSCIENCE, INC.
Entity Central Index Key	0000794172
Entity File Number	0-14902
Entity Tax Identification Number	31-0888197
Entity Incorporation, State or Country Code	OH
Current Fiscal Year End Date	--09-30
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Address, Address Line One	3471 River Hills Drive
Entity Address, City or Town	Cincinnati
Entity Address, State or Province	OH
Entity Address, Postal Zip Code	45244
City Area Code	513
Local Phone Number	271-3700
Trading Symbol	VIVO
Security Exchange Name	NASDAQ
Title of 12(b) Security	Common Stock
Entity Common Stock, Shares Outstanding		43,330,038

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Income Statement [Abstract]
NET REVENUES	$ 85,264	$ 57,296	$ 178,181	$ 104,717
COST OF SALES	27,492	22,750	58,861	42,520
GROSS PROFIT	57,772	34,546	119,320	62,197
OPERATING EXPENSES
Research and development	6,065	5,315	11,716	10,078
Selling and marketing	6,540	6,529	13,561	13,257
General and administrative	12,925	10,628	24,863	19,612
Acquisition-related costs		1,787		1,787
Change in fair value of acquisition consideration	(2,989)	(2,491)	(1,942)	(1,304)
Restructuring costs		252		527
Selected legal costs	1,030	735	2,257	1,055
Total operating expenses	23,571	22,755	50,455	45,012
OPERATING INCOME	34,201	11,791	68,865	17,185
OTHER INCOME (EXPENSE)
Interest income	6	23	15	134
Interest expense	(472)	(532)	(1,006)	(1,299)
RADx grant income	200		1,000
Other, net	(883)	1,365	(1,574)	653
Total other income (expense)	(1,149)	856	(1,565)	(512)
EARNINGS BEFORE INCOME TAXES	33,052	12,647	67,300	16,673
INCOME TAX PROVISION	6,750	3,288	14,219	4,487
NET EARNINGS	$ 26,302	$ 9,359	$ 53,081	$ 12,186
Earnings Per Share Data:
BASIC EARNINGS PER COMMON SHARE	$ 0.61	$ 0.22	$ 1.23	$ 0.28
DILUTED EARNINGS PER COMMON SHARE	$ 0.60	$ 0.22	$ 1.21	$ 0.28
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING—BASIC	43,244	42,830	43,171	42,810
EFFECT OF DILUTIVE STOCK OPTIONS AND RESTRICTED SHARE UNITS	878	138	789	143
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING—DILUTED	44,122	42,968	43,960	42,953
ANTI-DILUTIVE SECURITIES:
Common share options and restricted share units	166	1,635	169	1,520

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Statement of Comprehensive Income [Abstract]
NET EARNINGS	$ 26,302	$ 9,359	$ 53,081	$ 12,186
Other comprehensive income (loss):
Foreign currency translation adjustment	79	(2,786)	3,380	(18)
Unrealized gain (loss) on cash flow hedge	439	(313)	460	(313)
Reclassification of amortization of gain on cash flow hedge	(77)	(77)	(154)	(154)
Income taxes related to items of other comprehensive income (loss)	(80)	96	(66)	115
Other comprehensive income (loss), net of tax	361	(3,080)	3,620	(370)
COMPREHENSIVE INCOME	$ 26,663	$ 6,279	$ 56,701	$ 11,816

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES
Net earnings	$ 53,081	$ 12,186
Non-cash items included in net earnings:
Depreciation of property, plant and equipment	3,072	2,439
Amortization of intangible assets	4,363	3,449
Stock compensation expense	2,291	1,759
Deferred income taxes	(777)	656
Change in fair value of acquisition consideration	(1,942)	(1,304)
Change in the following:
Accounts receivable	(5,267)	(4,950)
Inventories	(12,185)	(2,511)
Prepaid expenses and other current assets	1,440	1,278
Accounts payable and accrued expenses	77	1,621
Income taxes payable	(2,698)	400
Other, net	36	692
Net cash provided by operating activities	41,491	15,715
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property, plant and equipment	(11,955)	(1,543)
Payment of acquisition consideration holdback	(5,000)
Net cash used in investing activities	(16,955)	(1,543)
CASH FLOWS FROM FINANCING ACTIVITIES
Payment on revolving credit facility	(18,824)	(27,000)
Payment of debt issuance costs		(116)
Proceeds from exercises of stock options	2,852
Net cash used in financing activities	(15,972)	(27,116)
Effect of Exchange Rate Changes on Cash and Cash Equivalents	1,296	97
Net Increase (Decrease) in Cash and Cash Equivalents	9,860	(12,847)
Cash and Cash Equivalents at Beginning of Period	53,514	62,397
Cash and Cash Equivalents at End of Period	$ 63,374	$ 49,550

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2021	Sep. 30, 2020
CURRENT ASSETS
Cash and cash equivalents	$ 63,374	$ 53,514
Accounts receivable, less allowances of $505 and $513, respectively	44,895	38,512
Inventories, net	72,534	61,264
Prepaid expenses and other current assets	7,491	8,900
Total current assets	188,294	162,190
PROPERTY, PLANT AND EQUIPMENT, at Cost
Land	991	991
Buildings and improvements	32,326	32,188
Machinery, equipment and furniture	74,173	69,854
Construction in progress	10,779	1,200
Subtotal	118,269	104,233
Less: accumulated depreciation and amortization	76,303	73,113
Property, plant and equipment, net	41,966	31,120
OTHER ASSETS
Goodwill	115,296	114,186
Other intangible assets, net	78,834	83,197
Right-of-use assets, net	6,297	6,336
Deferred income taxes	8,017	7,647
Other assets	465	585
Total other assets	208,909	211,951
TOTAL ASSETS	439,169	405,261
CURRENT LIABILITIES
Accounts payable	16,714	11,969
Accrued employee compensation costs	12,634	16,661
Current portion of acquisition consideration	11,296	12,619
Current operating lease obligations	1,892	1,789
Current government grant obligations	608	600
Other accrued expenses	5,664	5,362
Income taxes payable	1,502	3,524
Total current liabilities	50,310	52,524
NON-CURRENT LIABILITIES
Acquisition consideration	7,671	13,290
Post-employment benefits	2,429	2,493
Fair value of interest rate swaps	254	713
Long-term operating lease obligations	4,555	4,678
Long-term debt	50,000	68,824
Government grant obligations	10,537	10,524
Long-term income taxes payable	374	549
Deferred income taxes	3,389	3,804
Other non-current liabilities	177	233
Total non-current liabilities	79,386	105,108
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS' EQUITY
Preferred stock, no par value; 1,000,000 shares authorized; none issued
Common shares, no par value; 71,000,000 shares authorized, 43,329,294 and 43,068,842 shares issued, respectively
Additional paid-in capital	145,338	140,195
Retained earnings	162,375	109,294
Accumulated other comprehensive income (loss)	1,760	(1,860)
Total shareholders' equity	309,473	247,629
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 439,169	$ 405,261

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2021	Sep. 30, 2020
Statement of Financial Position [Abstract]
Allowances for accounts receivable	$ 505	$ 513
Preferred stock, par value	$ 0	$ 0
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0	$ 0
Common stock, shares authorized	71,000,000	71,000,000
Common stock, shares issued	43,329,294	43,068,842

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands	Total	Common Shares Issued [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Beginning balance at Sep. 30, 2019	$ 190,967		$ 132,834	$ 63,108	$ (4,975)
Beginning balance, Shares at Sep. 30, 2019		42,712,000
Conversion of restricted share units and exercise of stock options	(9)		(9)
Conversion of restricted share units and exercise of stock options, Shares		119,000
Stock compensation expense	1,759		1,759
Net earnings	12,186			12,186
Foreign currency translation adjustment	(18)				(18)
Hedging activity, net of tax	(352)				(352)
Ending balance at Mar. 31, 2020	204,533		134,584	75,294	(5,345)
Ending balance, Shares at Mar. 31, 2020		42,831,000
Beginning balance at Dec. 31, 2019	197,292		133,622	65,935	(2,265)
Beginning balance, Shares at Dec. 31, 2019		42,828,000
Conversion of restricted share units and exercise of stock options	(9)		(9)
Conversion of restricted share units and exercise of stock options, Shares		3,000
Stock compensation expense	971		971
Net earnings	9,359			9,359
Foreign currency translation adjustment	(2,786)				(2,786)
Hedging activity, net of tax	(294)				(294)
Ending balance at Mar. 31, 2020	204,533		134,584	75,294	(5,345)
Ending balance, Shares at Mar. 31, 2020		42,831,000
Beginning balance at Sep. 30, 2020	247,629		140,195	109,294	(1,860)
Beginning balance, Shares at Sep. 30, 2020		43,069,000
Conversion of restricted share units and exercise of stock options	2,852		2,852
Conversion of restricted share units and exercise of stock options, Shares		260,000
Stock compensation expense	2,291		2,291
Net earnings	53,081			53,081
Foreign currency translation adjustment	3,380				3,380
Hedging activity, net of tax	240				240
Ending balance at Mar. 31, 2021	309,473		145,338	162,375	1,760
Ending balance, Shares at Mar. 31, 2021		43,329,000
Beginning balance at Dec. 31, 2020	278,867		141,395	136,073	1,399
Beginning balance, Shares at Dec. 31, 2020		43,124,000
Conversion of restricted share units and exercise of stock options	2,893		2,893
Conversion of restricted share units and exercise of stock options, Shares		205,000
Stock compensation expense	1,050		1,050
Net earnings	26,302			26,302
Foreign currency translation adjustment	79				79
Hedging activity, net of tax	282				282
Ending balance at Mar. 31, 2021	$ 309,473		$ 145,338	$ 162,375	$ 1,760
Ending balance, Shares at Mar. 31, 2021		43,329,000

Nature of Business

Nature of Business	6 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business	1. Nature of Business Meridian Bioscience, Inc. (“Meridian” or “the Company”) was formed in 1976 and functions as a fully-integrated life science company with principal businesses in: (i) the development, manufacture, sale and distribution of diagnostic testing systems and kits, primarily for certain gastrointestinal and respiratory infectious diseases, and elevated blood lead levels; and (ii) the manufacture and distribution of bulk antigens, antibodies, immunoassay blocking reagents, various Polymerase Chain Reaction (“PCR”) master mixes, and bioresearch reagents used by other diagnostic manufacturers and researchers. Our reportable segments are Diagnostics and Life Science. The Diagnostics segment consists of: (i) manufacturing operations for infectious disease products in Cincinnati, Ohio; Quebec City, Canada; and Modi’in, Israel; (ii) manufacturing operations for blood chemistry products in Billerica, Massachusetts (near Boston); and (iii) the sale and distribution of diagnostics products domestically and abroad. This segment’s products are used by hospitals, reference labs and physician offices to detect infectious diseases and elevated lead levels in blood. The Life Science segment consists of: (i) manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; and Luckenwalde, Germany; and (ii) the sale and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents domestically and abroad, including a sales and business development facility, with outsourced distribution capabilities, in Beijing, China to pursue revenue opportunities in Asia. This segment’s products are used by manufacturers and researchers in a variety of applications (e.g., in-vitro

Basis of Presentation

Basis of Presentation	6 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	2. Basis of Presentation The Condensed Consolidated Financial Statements are unaudited and are prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“GAAP”) for interim financial information, and the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. In the opinion of Management, the Condensed Consolidated Financial Statements include all normal adjustments and disclosures necessary to present fairly the Company’s financial position as of March 31, 2021 and the results of its operations, cash flows and shareholders’ equity for the three- and six-month 10-K It should be noted that the terms revenue and/or revenues are utilized throughout these notes to the Condensed Consolidated Financial Statements to indicate net revenue and/or net revenues. The results of operations for interim periods are not necessarily indicative of the results to be expected for the year. In December 2019, the SARS-CoV-2 COVID-19 SARS-CoV-2) COVID-19. shelter-in-place non-essential While revenues within our Life Science segment have been positively impacted by the COVID-19 COVID-19 COVID-19 COVID-19 COVID-19 COVID-19 COVID-19 COVID-19 The preparation of these Condensed Consolidated Financial Statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities, at the date of the Condensed Consolidated Financial Statement s

Significant Accounting Policies

Significant Accounting Policies	6 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Significant Accounting Policies	3. Significant Accounting Policies A summary of the Company’s significant accounting policies is included in Note 1 to the audited consolidated financial statements of the Company’s fiscal 2020 Annual Report on Form 10-K (a) Recent Accounting Pronouncements – Pronouncements Adopted On October 1, 2020, the Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2016-13, Measurement of Credit Losses on Financial Instruments Pronouncements Issued but Not Yet Adopted as of March 31, 2021 In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes 2019-12”). 2019-12 2019-12 2019-12 (b) Reclassifications – Certain reclassifications have been made to the prior year Condensed Consolidated Financial Statements to conform to the current year presentation. Such reclassifications had no impact on net earnings or shareholders’ equity.

Revenue Recognition

Revenue Recognition	6 Months Ended
	Mar. 31, 2021
Revenue from Contract with Customer [Abstract]
Revenue Recognition	4. Revenue Recognition Overview Revenue from contracts with customers is recognized in an amount that reflects the consideration we expect to receive in exchange for products when obligations under such contracts are satisfied. Revenue is generally recognized at a point-in-time Revenue Disaggregation The following tables present our revenues disaggregated by major geographic region, major product platform and disease state (Diagnostics segment only): Revenue by Reportable Segment & Geographic Region Three Months Ended March 31, Six Months Ended March 31, 2021 2020 Inc (Dec) 2021 2020 Inc (Dec) Diagnostics- Americas $ 25,290 $ 27,670 (9 )% $ 48,824 $ 55,405 (12 )% EMEA 6,071 6,777 (10 )% 12,101 13,277 (9 )% ROW 588 495 19 % 1,345 1,051 28 % Total Diagnostics 31,949 34,942 (9 )% 62,270 69,733 (11 )% Life Science- Americas 13,550 4,612 194 % 32,296 8,623 275 % EMEA 21,773 9,946 119 % 54,066 14,907 263 % ROW 17,992 7,796 131 % 29,549 11,454 158 % Total Life Science 53,315 22,354 139 % 115,911 34,984 231 % Consolidated $ 85,264 $ 57,296 49 % $ 178,181 $ 104,717 70 % Revenue by Product Platform/Type Three Months Ended March 31, Six Months Ended March 31, 2021 2020 Inc (Dec) 2021 2020 Inc (Dec) Diagnostics- Molecular assays $ 4,395 $ 7,238 (39 )% $ 8,985 $ 14,077 (36 )% Non-molecular 27,554 27,704 (1 )% 53,285 55,656 (4 )% Total Diagnostics $ 31,949 $ 34,942 (9 )% $ 62,270 $ 69,733 (11 )% Life Science- Molecular reagents $ 37,752 $ 11,534 227 % $ 83,776 $ 16,902 396 % Immunological reagents 15,563 10,820 44 % 32,135 18,082 78 % Total Life Science $ 53,315 $ 22,354 139 % $ 115,911 $ 34,984 231 % Revenue by Disease State (Diagnostics segment only) Three Months Ended March 31, Six Months Ended March 31, 2021 2020 Inc (Dec) 2021 2020 Inc (Dec) Diagnostics- Gastrointestinal assays $ 15,666 $ 14,014 12 % $ 31,118 $ 30,060 4 % Respiratory illness assays 3,686 10,863 (66 )% 8,492 18,612 (54 )% Blood chemistry assays 4,358 4,194 4 % 8,753 9,142 (4 )% Other 8,239 5,871 40 % 13,907 11,919 17 % Total Diagnostics $ 31,949 $ 34,942 (9 )% $ 62,270 $ 69,733 (11 )% Royalty Income Royalty income received from DiaSorin, which primarily related to sales of H. pylori Non-molecular Reagent Rental Arrangements Revenue allocated to the lease elements of Reagent Rental arrangements totaled approximately $900 and $1,125 in the three months ended March 31, 2021 and 2020, respectively, and $1,780 and 2,250 in the six months ended March 31, 2021 and 2020, respectively. Such revenue is included as part of net revenues in our Condensed Consolidated Statements of Operations.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	5. Fair Value Measurements Certain asset s Fair Value Measurements and Disclosures Assets and liabilities measured and reported at fair value are classified and disclosed in one of the following categories based on inputs: Level 1 Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities Level 2 Quoted prices in markets that are not active and financial instruments for which all significant inputs are observable, either directly or indirectly Level 3 Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable T The fair values of the interest rate swap agreements were determined by reference to a third-party valuation and is considered a Level 2 input within the fair value hierarchy of valuation techniques. As described in Note 6, we acquired Exalenz Bioscience Ltd. (“Exalenz”) in fiscal 2020. The fair values of the acquired accounts receivable, inventories, property, plant and equipment, and other current assets and the fair values of the assumed accounts payable and accrued expenses were valued using Level 2 inputs, which included data points that were observable, such as appraisals or established values of comparable assets (market approach). Intangible assets were valued using Level 3 inputs, which are unobservable by nature, and included internal estimates of future cash flows (income approach). Significant increases (decreases) in any of those unobservable inputs, as of the date of the acquisition, in isolation would result in a significantly lower (higher) fair value measurement. Management engaged a third-party valuation firm to assist in the determination of the preliminary purchase accounting fair values, and specifically those considered Level 3 measurements. Management ultimately oversees the third-party valuation firm to ensure that the transaction-specific assumptions are appropriate for the Company. In connection with the acquisition of the business of GenePOC, Inc. (“GenePOC”) in fiscal 2019 and subsequent amendments to modify certain terms of the agreement related to contingent consideration achievement levels and milestone dates, the Company is required to make contingent consideration payments of up to earn-out s significantly from The following table provides information by level for financial assets and liabilities that are measured at fair value on a recurring basis: Fair Value Measurements Using Carrying Value Level 1 Level 2 Level 3 Interest rate swaps - As of March 31, 2021 $ (254 ) $ — $ (254 ) $ — As of September 30, 2020 $ (713 ) $ — $ (713 ) $ — Contingent consideration - As of March 31, 2021 $ (18,967 ) $ — $ — $ (18,967 ) As of September 30, 2020 $ (20,909 ) $ — $ — $ (20,909 )

Business Combinations

Business Combinations	6 Months Ended
	Mar. 31, 2021
Business Combinations [Abstract]
Business Combinations	6. Business Combinations On April 30, 2020 (“the acquisition date”), we acquired % of the outstanding common shares and voting interest of Exalenz, a Modi’in, Israel based provider of the BreathID ® Helicobacter pylori. Cash consideration totaled million New Israeli Shekels (“NIS”), which equated to $ at the date of closing. Including debt assumed and repaid shortly after closing, the total consideration transferred was $ . To finance the acquisition, the Company utilized cash and cash equivalents on hand and proceeds drawn from our revolving credit facility (see Note 11). In anticipation of the transaction, we executed forward currency contracts to acquire the NIS required for the acquisition. As a result, the net cash outlay for the transaction prior to the repayment of debt was $ . As a result of total consideration exceeding the preliminary fair value of the net assets acquired, goodwill in the amount of $24,827 was recorded in connection with this acquisition, none of which will be deductible for U.S. tax purposes. The goodwill results largely from our ability to market and sell the BreathID platform through our established customer base and distribution channels. The Company’s consolidated results for the three and six months ended March 31, 2021 include the following from Exalenz: Three March 31, Six March 31, Net revenues $ 2,784 $ 5,882 Net loss $ (947 ) $ (1,739 ) These results for the three and six months ended March 31, 2021, which are reported as part of the Diagnostics segment, include $720 and , respectively, of non-compete The recognized preliminary amounts of identifiable assets acquired and liabilities assumed in the acquisition of Exalenz are as follows: PRELIMINARY April 30, (as initially Measurement April 30, (as adjusted) Fair value of assets acquired - Cash $ 5,006 $ — $ 5,006 Accounts receivable 637 — 637 Inventories 4,329 (296 ) 4,033 Other current assets 851 1,825 2,676 Property, plant and equipment 544 (16 ) 528 Goodwill 29,288 (4,461 ) 24,827 Other intangible assets (estimated useful life): Non-compete 120 (10 ) 110 Trade name (10 years) 3,540 320 3,860 Technology (15 years) 5,590 530 6,120 Customer relationships (10 years) 19,370 1,270 20,640 Right-of-use 1,358 (47 ) 1,311 Deferred tax assets, net 5,566 1,178 6,744 76,199 293 76,492 Fair value of liabilities assumed - Accounts payable and accrued expenses (including current portion of lease and government grant obligations) 7,757 251 8,008 Long-term lease obligations 1,054 42 1,096 Long-term government grant obligations 10,792 — 10,792 Other non-current 291 — 291 19,894 293 20,187 Total consideration paid (including $8,068 to pay off long-term debt) $ 56,305 $ — $ 56,305 As indicated, the allocation of the purchase price is preliminary, pending final completion of valuations. As a result of further refining its estimates and assumptions since the date of the acquisition, the Company recorded measurement period adjustments to the initial opening balance sheet as shown in the table above. Adjustments were primarily made to other current assets, goodwill, other intangible assets, and deferred tax assets. There were no measurement period adjustments materially impacting net earnings that would have been recorded in previous reporting periods if the adjustments had been recognized as of the acquisition date. Currently, we are primarily assessing the results of the valuation of intangible assets and the tax implications thereon. Upon completion of these analyses, any required adjustments are expected to result in an amount being reclassified among goodwill, other intangible assets and deferred taxes, as applicable. Pro Forma Information The following table provides the unaudited condensed consolidated pro forma results for the periods presented as if Exalenz had been acquired as of the beginning of fiscal 2020 (October 1, 2019). Pro forma results do not include the effect of any synergies achieved or anticipated to be achieved from the acquisition, and accordingly, are not necessarily indicative of the results that would have occurred if the acquisition had occurred on the date indicated or that may result in the future. Three Months Ended March 31, Six Months Ended March 31, 2021 2020 2021 2020 Net revenues $ 85,264 $ 60,701 $ 178,181 $ 111,895 Net earnings $ 26,302 $ 8,064 $ 53,081 $ 9,246 These unaudited pro forma amounts have been calculated by including the results of Exalenz and adjusting the results to give effect to the following, as if the acquisition had been consummated on October 1, 2019, together with the consequential tax effects thereon: Three Months Six Months Ended 2021 2020 2021 2020 Adjustments to net revenues Exalenz pre-acquisition net revenues $ — $ 3,405 $ — $ 7,178 Adjustments to net earnings Exalenz pre-acquisition net loss $ — $ (752 ) $ — $ (1,504 ) Pro forma adjustments: Remove net impact of non-continuing — 490 — 591 Incremental depreciation and amortization — (911 ) — (1,824 ) Incremental interest costs, net — (381 ) — (772 ) Tax effects of pro forma adjustments and recognizing benefit on — 259 — 569 Total adjustments to net earnings $ — $ (1,295 ) $ — $ (2,940 )

Cash and Cash Equivalents

Cash and Cash Equivalents	6 Months Ended
	Mar. 31, 2021
Cash and Cash Equivalents [Abstract]
Cash and Cash Equivalents	7. Cash and Cash Equivalents Cash and cash equivalents include the following: March 31, September 30, Institutional money market funds $ 1,017 $ 1,017 Cash on hand, unrestricted 62,357 52,497 Total $ 63,374 $ 53,514

Inventories, Net

Inventories, Net	6 Months Ended
	Mar. 31, 2021
Inventory Disclosure [Abstract]
Inventories, Net	8. Inventories, Net Inventories, net are comprised of the following: March 31, September 30, Raw materials $ 18,706 $ 11,966 Work-in-process 22,987 19,477 Finished goods - instruments 1,933 1,594 Finished goods - kits and reagents 28,908 28,227 Total $ 72,534 $ 61,264

Leasing Arrangements

Leasing Arrangements	6 Months Ended
	Mar. 31, 2021
Leases [Abstract]
Leasing Arrangements	9. Leasing Arrangements The Company is party to a number of operating leases, the majority of which are related to office, warehouse and manufacturing space. The related operating lease assets and obligations are reflected within right-of-use The lease costs for these operating leases reflected in Three Months Ended March 31, Six Months Ended March 31, 2021 2020 2021 2020 Lease costs within cost of sales $ 198 $ 130 $ 356 $ 259 Lease costs within operating expenses 387 292 761 559 Right-of-use 612 222 692 222 In addition, the Company periodically enters into other short-term operating leases, generally with an initial term of twelve months or less. These leases are not recorded on the Condensed Consolidated Balance Sheets and the related lease expense is immaterial for the three and six months ended March 31, 2021 and 2020. The Company often has options to renew lease terms, with the exercise of lease renewal options generally at the Company’s sole discretion. In addition, certain lease arrangements may be terminated prior to their original expiration date at our discretion. We evaluate renewal and termination options at the lease commencement date to determine if we are reasonably certain to exercise the option on the basis of economic factors. The discount rate implicit within our leases is generally not determin a March 31, September 30, Weighted average remaining lease term 3.8 years 4.2 years Average discount rate 3.4 % 3.7 % Maturities of lease liabilities by fiscal year for the Company’s operating leases were 2021 (represents remainder of fiscal year) $ 1,108 2022 2,016 2023 1,482 2024 1,108 2025 806 Thereafter 331 Total lease payments 6,851 Less amount of lease payments representing interest (404 ) Total present value of lease payments $ 6,447 Supplemental cash flow information related to the Company’s operating leases are as follows: Six Months Ended March 31, 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 1,072 $ 778

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets, Net	6 Months Ended
	Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets, Net	10. Goodwill and Other Intangible Assets, Net During the six A summary of other intangible assets, net subject to amortization is as follows: March 31, 2021 September 30, 2020 Gross Accumulated Gross Accumulated Manufacturing technologies, core products and cell lines $ 62,446 $ 20,756 $ 62,363 $ 18,750 Trade names, licenses and patents 18,524 8,813 18,425 7,801 Customer lists, customer relationships and supply agreements 45,287 17,944 45,071 16,210 Government grants 858 858 810 810 Non-compete 110 20 110 11 Total $ 127,225 $ 48,391 $ 126,779 $ 43,582 The aggregate amortization expense for these other intangible assets was $2,142 and $1,727 for the three months ended March 31, 2021 and 2020, respectively , and for the six months ended March 31, 2021 and 2020, respectively. The estimated aggregate amortization expense for these other intangible assets for each of the fiscal years through fiscal 2026 is as follows: remainder of fiscal 2021 – $4,210, fiscal 2022 – $8,000, fiscal 2023 – $7,975, fiscal 2024 – $7,975, fiscal 2025 – $7,950, and fiscal 2026 – $7,300.

Bank Credit Arrangements

Bank Credit Arrangements	6 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
Bank Credit Arrangements	11. Bank Cred i In anticipation of the acquisition of the business of GenePOC, on May 24, 2019 , , three months respectively, and on-hand, 2020, The revolving credit facility is collateralized by the business assets of the Company’s U.S. subsidiaries and requires compliance with financial covenants that limit the amount of debt obligations and require a minimum level of coverage of fixed charges, as defined in the revolving credit facility agreement. As of March 31, 2021, the Company was in compliance with all covenants.

Contingent Obligations and Non-

Contingent Obligations and Non-Current Liabilities	6 Months Ended
	Mar. 31, 2021
Contingent Obligations and NonCurrent Liabilities Disclosure [Abstract]
Contingent Obligations and Non-Current Liabilities	12. Contingent Obligations and Non-Current In connection with the acquisition of Exalenz (see Note 6), the Company assumed several Israeli government grant obligations. The repayment of the grants, along with interest incurred at varying stated fixed rates based on LIBOR at the time each grant was received (ranging from 0.58% to 6.60%), is not dictated by an established repayment schedule. Rather, the grants and related interest are required to be repaid using 3% of the revenues generated from the sales of BreathID products, with the timing of repayment contingent upon the level and timing of such revenues. In addition, the grants have no collateral or financial covenant provisions generally associated with traditional borrowing instruments. These obligation amounts total $11,145 and $11,124 as of March 31, 2021 and September 30, 2020, respectively, and are reflected in the Condensed Consolidated Balance Sheets as follows: March 31, 2021 September 30, Current liabilities $ 608 $ 600 Non-current $ 10,537 $ 10,524 Additionally, the Company has provided certain post-employment benefits to its former Chief Executive Officer, and these obligations total $1,748 and $1,840 at March 31, 2021 and September 30, 2020, respectively. In addition, the Company is required by the governments of certain foreign countries in which we operate to maintain a level of accrual s

National Institutes of Health C

National Institutes of Health Contracts	6 Months Ended
	Mar. 31, 2021
Research and Development [Abstract]
National Institutes of Health Contracts	13. National Institutes of Health Contracts In December 2020, the Company entered into a sub-award SARS-CoV-2 recorded i Effective February 1, 2021, the Company entered into a second grant contract under the RADx initiative, the purpose of which is to support the Company’s manufacturing production scale-up COVID-19 COVID-19

Reportable Segment and Major Cu

Reportable Segment and Major Customers Information	6 Months Ended
	Mar. 31, 2021
Segment Reporting [Abstract]
Reportable Segments and Major Customers Data	14. Reportable Segment and Major Customers Information During the three and six months ended March 31, 2021, products related to COVID-19 respectively, of Life Science segment revenues, and 37% and 41%, respectively, of consolidated revenues. In addition, during the three and six months ended March 31, 2021 and 2020, no individual Diagnostics or Life Science segment customer accounted for Individual Diagnostics or Life Science segment customers, including their affiliates, comprising 10% or more of reportable segment revenues during any of the three- and six-month 0 Three Months Ended March 31, Six Months Ended March 31, 2021 2020 2021 2020 Diagnostics Customer A 10 % 9 % 11 % 11 % Customer B 10 % 13 % 10 % 14 % Customer C 11 % 5 % 11 % 5 % Life Science Customer D 9 % 13 % 6 % 11 % Customer E 9 % 5 % 14 % 4 % In addition, during both the three and six mo n Two Life Science segment customers accounted for the following significant percentages of consolidated accounts receivable: March 31, September 30, Customer D 10 % 8 % Customer E 3 % 15 % Reportable segment information for the inte r Diagnostics Life Science Corporate (1) Eliminations (2) Total Three Months Ended March 31, 2021 Net revenues - Third-party $ 31,949 $ 53,315 $ — $ — $ 85,264 Inter-segment 116 91 — (207 ) — Operating income 2,421 36,089 (4,325 ) 16 34,201 Goodwill (March 31, 2021) 95,283 20,013 — — 115,296 Other intangible assets, net (March 31, 2021) 78,832 2 — — 78,834 Total assets (March 31, 2021) 313,271 125,947 — (49 ) 439,169 Three Months Ended March 31, 2020 Net revenues - Third-party $ 34,942 $ 22,354 $ — $ — $ 57,296 Inter-segment 81 55 — (136 ) — Operating income 4,729 9,931 (2,896 ) 27 11,791 Goodwill (September 30, 2020) 94,855 19,331 — — 114,186 Other intangible assets, net (September 30, 2020) 83,179 18 — — 83,197 Total assets (September 30, 2020) 306,812 98,483 — (34 ) 405,261 Six Months Ended March 31, 2021 Net revenues - Third-party $ 62,270 $ 115,911 $ — $ — $ 178,181 Inter-segment 185 109 — (294 ) — Operating income 1,239 75,886 (8,288 ) 28 68,865 Six Months Ended March 31, 2020 Net revenues - Third-party $ 69,733 $ 34,984 $ — $ — $ 104,717 Inter-segment 178 120 — (298 ) — Operating income 9,870 12,259 (4,983 ) 39 17,185 (1) Includes selected legal costs of in the three and six months ended March 31, 2021, respectively, and restructuring costs and selected legal costs of in the three and six months ended March 31, 2020, respectively. (2) Eliminations consist of inter-segment transactions. A reconciliation of reportable segment operating income to consolidated earnings before income taxes for the interim periods is as follows: Three Months Ended Six Months Ended March 31, March 31, 2021 2020 2021 2020 Operating income: Diagnostics segment $ 2,421 $ 4,729 $ 1,239 $ 9,870 Life Science segment 36,089 9,931 75,886 12,259 Eliminations 16 27 28 39 Total operating income 38,526 14,687 77,153 22,168 Corporate operating expenses (4,325 ) (2,896 ) (8,288 ) (4,983 ) Interest income 6 23 15 134 Interest expense (472 ) (532 ) (1,006 ) (1,299 ) RADx initiative grant income 200 — 1,000 — Other, net (883 ) 1,365 (1,574 ) 653 Consolidated earnings before income taxes $ 33,052 $ 12,647 $ 67,300 $ 16,673 Transactions betw e .

Income Taxes

Income Taxes	6 Months Ended
	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	15. Income Taxes The effective rate for inco m for the three and six months ended March 31, 2021, respectively, and for the three and six months ended March 31, 2020. The lower fiscal 2021 effective tax rates result primarily from the combined effects of the following: (i) a significantly higher percentage of earnings before income taxes being generated in foreign jurisdictions with tax rates lower than the U.S., particularly the United Kingdom (“U.K.”); (ii) the non-deductibility of a significant portion of the acquisition-related costs related to Exalenz; and (iii) the tax impact of restricted share unit lapses and stock option exercises occurring on dates when the share price of Company stock was significantly higher than the share price on the date such equity awards were granted.

Litigation Matters

Litigation Matters	6 Months Ended
	Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Litigation Matters	16. Litigation Matters On April 17, 2018, Magellan r e of expense for attorneys’ fees related to this matter is included within the Condensed Consolidated Statements of Operations for the three months ended March 31, 2021 and 2020, respectively, and approximately for the six months ended March 31, 2021 and 2020, respectively.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	6 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Recent Accounting Pronouncements	(a) Recent Accounting Pronouncements – Pronouncements Adopted On October 1, 2020, the Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2016-13, Measurement of Credit Losses on Financial Instruments Pronouncements Issued but Not Yet Adopted as of March 31, 2021 In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes 2019-12”). 2019-12 2019-12 2019-12
Reclassifications	(b) Reclassifications – Certain reclassifications have been made to the prior year Condensed Consolidated Financial Statements to conform to the current year presentation. Such reclassifications had no impact on net earnings or shareholders’ equity.

Revenue Recognition (Tables)

Revenue Recognition (Tables)	6 Months Ended
	Mar. 31, 2021
Revenue Recognition [Abstract]
Summary of Disaggregation of Revenue	Revenue by Reportable Segment & Geographic Region Three Months Ended March 31, Six Months Ended March 31, 2021 2020 Inc (Dec) 2021 2020 Inc (Dec) Diagnostics- Americas $ 25,290 $ 27,670 (9 )% $ 48,824 $ 55,405 (12 )% EMEA 6,071 6,777 (10 )% 12,101 13,277 (9 )% ROW 588 495 19 % 1,345 1,051 28 % Total Diagnostics 31,949 34,942 (9 )% 62,270 69,733 (11 )% Life Science- Americas 13,550 4,612 194 % 32,296 8,623 275 % EMEA 21,773 9,946 119 % 54,066 14,907 263 % ROW 17,992 7,796 131 % 29,549 11,454 158 % Total Life Science 53,315 22,354 139 % 115,911 34,984 231 % Consolidated $ 85,264 $ 57,296 49 % $ 178,181 $ 104,717 70 % Revenue by Product Platform/Type Three Months Ended March 31, Six Months Ended March 31, 2021 2020 Inc (Dec) 2021 2020 Inc (Dec) Diagnostics- Molecular assays $ 4,395 $ 7,238 (39 )% $ 8,985 $ 14,077 (36 )% Non-molecular 27,554 27,704 (1 )% 53,285 55,656 (4 )% Total Diagnostics $ 31,949 $ 34,942 (9 )% $ 62,270 $ 69,733 (11 )% Life Science- Molecular reagents $ 37,752 $ 11,534 227 % $ 83,776 $ 16,902 396 % Immunological reagents 15,563 10,820 44 % 32,135 18,082 78 % Total Life Science $ 53,315 $ 22,354 139 % $ 115,911 $ 34,984 231 % Revenue by Disease State (Diagnostics segment only) Three Months Ended March 31, Six Months Ended March 31, 2021 2020 Inc (Dec) 2021 2020 Inc (Dec) Diagnostics- Gastrointestinal assays $ 15,666 $ 14,014 12 % $ 31,118 $ 30,060 4 % Respiratory illness assays 3,686 10,863 (66 )% 8,492 18,612 (54 )% Blood chemistry assays 4,358 4,194 4 % 8,753 9,142 (4 )% Other 8,239 5,871 40 % 13,907 11,919 17 % Total Diagnostics $ 31,949 $ 34,942 (9 )% $ 62,270 $ 69,733 (11 )%

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Summary of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table provides information by level for financial assets and liabilities that are measured at fair value on a recurring basis: Fair Value Measurements Using Carrying Value Level 1 Level 2 Level 3 Interest rate swaps - As of March 31, 2021 $ (254 ) $ — $ (254 ) $ — As of September 30, 2020 $ (713 ) $ — $ (713 ) $ — Contingent consideration - As of March 31, 2021 $ (18,967 ) $ — $ — $ (18,967 ) As of September 30, 2020 $ (20,909 ) $ — $ — $ (20,909 )

Business Combinations (Tables)

Business Combinations (Tables)	6 Months Ended
	Mar. 31, 2021
Business Acquisition [Line Items]
Business Acquisition, Pro Forma Information	Three Months Ended March 31, Six Months Ended March 31, 2021 2020 2021 2020 Net revenues $ 85,264 $ 60,701 $ 178,181 $ 111,895 Net earnings $ 26,302 $ 8,064 $ 53,081 $ 9,246
Business Acquisition Proforma Adjustments	Three Months Six Months Ended 2021 2020 2021 2020 Adjustments to net revenues Exalenz pre-acquisition net revenues $ — $ 3,405 $ — $ 7,178 Adjustments to net earnings Exalenz pre-acquisition net loss $ — $ (752 ) $ — $ (1,504 ) Pro forma adjustments: Remove net impact of non-continuing — 490 — 591 Incremental depreciation and amortization — (911 ) — (1,824 ) Incremental interest costs, net — (381 ) — (772 ) Tax effects of pro forma adjustments and recognizing benefit on — 259 — 569 Total adjustments to net earnings $ — $ (1,295 ) $ — $ (2,940 )
Exalenz [Member]
Business Acquisition [Line Items]
Summary of Business Acquisitions, by Acquisition	The Company’s consolidated results for the three and six months ended March 31, 2021 include the following from Exalenz: Three March 31, Six March 31, Net revenues $ 2,784 $ 5,882 Net loss $ (947 ) $ (1,739 )
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The recognized preliminary amounts of identifiable assets acquired and liabilities assumed in the acquisition of Exalenz are as follows: PRELIMINARY April 30, (as initially Measurement April 30, (as adjusted) Fair value of assets acquired - Cash $ 5,006 $ — $ 5,006 Accounts receivable 637 — 637 Inventories 4,329 (296 ) 4,033 Other current assets 851 1,825 2,676 Property, plant and equipment 544 (16 ) 528 Goodwill 29,288 (4,461 ) 24,827 Other intangible assets (estimated useful life): Non-compete 120 (10 ) 110 Trade name (10 years) 3,540 320 3,860 Technology (15 years) 5,590 530 6,120 Customer relationships (10 years) 19,370 1,270 20,640 Right-of-use 1,358 (47 ) 1,311 Deferred tax assets, net 5,566 1,178 6,744 76,199 293 76,492 Fair value of liabilities assumed - Accounts payable and accrued expenses (including current portion of lease and government grant obligations) 7,757 251 8,008 Long-term lease obligations 1,054 42 1,096 Long-term government grant obligations 10,792 — 10,792 Other non-current 291 — 291 19,894 293 20,187 Total consideration paid (including $8,068 to pay off long-term debt) $ 56,305 $ — $ 56,305

Cash and Equivalents (Tables)

Cash and Equivalents (Tables)	6 Months Ended
	Mar. 31, 2021
Cash and Cash Equivalents [Abstract]
Components of Cash and Cash Equivalents	Cash and cash equivalents include the following: March 31, September 30, Institutional money market funds $ 1,017 $ 1,017 Cash on hand, unrestricted 62,357 52,497 Total $ 63,374 $ 53,514

Inventories, Net (Tables)

Inventories, Net (Tables)	6 Months Ended
	Mar. 31, 2021
Inventory Disclosure [Abstract]
Components of Inventories	Inventories, net are comprised of the following: March 31, September 30, Raw materials $ 18,706 $ 11,966 Work-in-process 22,987 19,477 Finished goods - instruments 1,933 1,594 Finished goods - kits and reagents 28,908 28,227 Total $ 72,534 $ 61,264

Leasing Arrangements (Tables)

Leasing Arrangements (Tables)	6 Months Ended
	Mar. 31, 2021
Leases [Abstract]
Schedule of condensed income statement of operation	The lease costs for these operating leases reflected in Three Months Ended March 31, Six Months Ended March 31, 2021 2020 2021 2020 Lease costs within cost of sales $ 198 $ 130 $ 356 $ 259 Lease costs within operating expenses 387 292 761 559 Right-of-use 612 222 692 222
Schedule of maturities of lease liabilities	Maturities of lease liabilities by fiscal year for the Company’s operating leases were 2021 (represents remainder of fiscal year) $ 1,108 2022 2,016 2023 1,482 2024 1,108 2025 806 Thereafter 331 Total lease payments 6,851 Less amount of lease payments representing interest (404 ) Total present value of lease payments $ 6,447
Schedule of weighted average remaining lease term and discount rate	The weighted average remaining lease term for our operating leases and the weighted average discount rate used to measure our operating leases as of March 31, 2021 and September 30, 2020 were as follows: March 31, September 30, Weighted average remaining lease term 3.8 years 4.2 years Average discount rate 3.4 % 3.7 %
Schedule of supplemental cash flow information related to the companys operating lease liabilities	Supplemental cash flow information related to the Company’s operating leases are as follows: Six Months Ended March 31, 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 1,072 $ 778

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets, Net (Tables)	6 Months Ended
	Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of acquired intangible assets subject to amortization	A summary of other intangible assets, net subject to amortization is as follows: March 31, 2021 September 30, 2020 Gross Accumulated Gross Accumulated Manufacturing technologies, core products and cell lines $ 62,446 $ 20,756 $ 62,363 $ 18,750 Trade names, licenses and patents 18,524 8,813 18,425 7,801 Customer lists, customer relationships and supply agreements 45,287 17,944 45,071 16,210 Government grants 858 858 810 810 Non-compete 110 20 110 11 Total $ 127,225 $ 48,391 $ 126,779 $ 43,582

Contingent Obligations and No_2

Contingent Obligations and Non-Current Liabilities (Tables)	6 Months Ended
	Mar. 31, 2021
Contingent Obligations and NonCurrent Liabilities Disclosure [Abstract]
Schedule of Government Grant Obligations Reflected in Condensed Consolidated Balance Sheet	These obligation amounts total $11,145 and $11,124 as of March 31, 2021 and September 30, 2020, respectively, and are reflected in the Condensed Consolidated Balance Sheets as follows: March 31, 2021 September 30, Current liabilities $ 608 $ 600 Non-current $ 10,537 $ 10,524

Reportable Segment and Major _2

Reportable Segment and Major Customers Information (Tables)	6 Months Ended
	Mar. 31, 2021
Segment Reporting [Abstract]
Consolidated Net Revenues	Individual Diagnostics or Life Science segment customers, including their affiliates, comprising 10% or more of reportable segment revenues during any of the three- and six-month 0 Three Months Ended March 31, Six Months Ended March 31, 2021 2020 2021 2020 Diagnostics Customer A 10 % 9 % 11 % 11 % Customer B 10 % 13 % 10 % 14 % Customer C 11 % 5 % 11 % 5 % Life Science Customer D 9 % 13 % 6 % 11 % Customer E 9 % 5 % 14 % 4 % In addition, during both the three and six mo n Two Life Science segment customers accounted for the following significant percentages of consolidated accounts receivable: March 31, September 30, Customer D 10 % 8 % Customer E 3 % 15 %
Reportable segment Information	Reportable segment information for the inte r Diagnostics Life Science Corporate (1) Eliminations (2) Total Three Months Ended March 31, 2021 Net revenues - Third-party $ 31,949 $ 53,315 $ — $ — $ 85,264 Inter-segment 116 91 — (207 ) — Operating income 2,421 36,089 (4,325 ) 16 34,201 Goodwill (March 31, 2021) 95,283 20,013 — — 115,296 Other intangible assets, net (March 31, 2021) 78,832 2 — — 78,834 Total assets (March 31, 2021) 313,271 125,947 — (49 ) 439,169 Three Months Ended March 31, 2020 Net revenues - Third-party $ 34,942 $ 22,354 $ — $ — $ 57,296 Inter-segment 81 55 — (136 ) — Operating income 4,729 9,931 (2,896 ) 27 11,791 Goodwill (September 30, 2020) 94,855 19,331 — — 114,186 Other intangible assets, net (September 30, 2020) 83,179 18 — — 83,197 Total assets (September 30, 2020) 306,812 98,483 — (34 ) 405,261 Six Months Ended March 31, 2021 Net revenues - Third-party $ 62,270 $ 115,911 $ — $ — $ 178,181 Inter-segment 185 109 — (294 ) — Operating income 1,239 75,886 (8,288 ) 28 68,865 Six Months Ended March 31, 2020 Net revenues - Third-party $ 69,733 $ 34,984 $ — $ — $ 104,717 Inter-segment 178 120 — (298 ) — Operating income 9,870 12,259 (4,983 ) 39 17,185 (1) Includes selected legal costs of in the three and six months ended March 31, 2021, respectively, and restructuring costs and selected legal costs of in the three and six months ended March 31, 2020, respectively. (2) Eliminations consist of inter-segment transactions.
Pre-tax Earnings Table	A reconciliation of reportable segment operating income to consolidated earnings before income taxes for the interim periods is as follows: Three Months Ended Six Months Ended March 31, March 31, 2021 2020 2021 2020 Operating income: Diagnostics segment $ 2,421 $ 4,729 $ 1,239 $ 9,870 Life Science segment 36,089 9,931 75,886 12,259 Eliminations 16 27 28 39 Total operating income 38,526 14,687 77,153 22,168 Corporate operating expenses (4,325 ) (2,896 ) (8,288 ) (4,983 ) Interest income 6 23 15 134 Interest expense (472 ) (532 ) (1,006 ) (1,299 ) RADx initiative grant income 200 — 1,000 — Other, net (883 ) 1,365 (1,574 ) 653 Consolidated earnings before income taxes $ 33,052 $ 12,647 $ 67,300 $ 16,673

Revenue Recognition - Summary o

Revenue Recognition - Summary of Disaggregation of Revenue by Reportable Segment and Geographic Region (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 85,264	$ 57,296	$ 178,181	$ 104,717
Revenue, % change	49.00%		70.00%
Diagnostics [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 31,949	34,942	$ 62,270	69,733
Revenue, % change	(9.00%)		(11.00%)
Diagnostics [Member] | Americas [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 25,290	27,670	$ 48,824	55,405
Revenue, % change	(9.00%)		(12.00%)
Diagnostics [Member] | EMEA [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 6,071	6,777	$ 12,101	13,277
Revenue, % change	(10.00%)		(9.00%)
Diagnostics [Member] | ROW [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 588	495	$ 1,345	1,051
Revenue, % change	19.00%		28.00%
Life Science [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 53,315	22,354	$ 115,911	34,984
Revenue, % change	139.00%		231.00%
Life Science [Member] | Americas [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 13,550	4,612	$ 32,296	8,623
Revenue, % change	194.00%		275.00%
Life Science [Member] | EMEA [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 21,773	9,946	$ 54,066	14,907
Revenue, % change	119.00%		263.00%
Life Science [Member] | ROW [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 17,992	$ 7,796	$ 29,549	$ 11,454
Revenue, % change	131.00%		158.00%

Revenue Recognition - Summary_2

Revenue Recognition - Summary of Disaggregation of Revenue by Product Platform/Type (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Segment Reporting Information [Line Items]
Revenue	$ 85,264	$ 57,296	$ 178,181	$ 104,717
Revenue, % change	49.00%		70.00%
Diagnostics [Member]
Segment Reporting Information [Line Items]
Revenue	$ 31,949	34,942	$ 62,270	69,733
Revenue, % change	(9.00%)		(11.00%)
Diagnostics [Member] | Molecular Assays [Member]
Segment Reporting Information [Line Items]
Revenue	$ 4,395	7,238	$ 8,985	14,077
Revenue, % change	(39.00%)		(36.00%)
Diagnostics [Member] | Non-molecular assays
Segment Reporting Information [Line Items]
Revenue	$ 27,554	27,704	$ 53,285	55,656
Revenue, % change	(1.00%)		(4.00%)
Life Science [Member]
Segment Reporting Information [Line Items]
Revenue	$ 53,315	22,354	$ 115,911	34,984
Revenue, % change	139.00%		231.00%
Life Science [Member] | Molecular Reagents [Member]
Segment Reporting Information [Line Items]
Revenue	$ 37,752	11,534	$ 83,776	16,902
Revenue, % change	227.00%		396.00%
Life Science [Member] | Immunological Reagents [Member]
Segment Reporting Information [Line Items]
Revenue	$ 15,563	$ 10,820	$ 32,135	$ 18,082
Revenue, % change	44.00%		78.00%

Revenue Recognition - Summary_3

Revenue Recognition - Summary of Disaggregation of Revenue by Disease State (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Segment Reporting Information [Line Items]
Revenue	$ 85,264	$ 57,296	$ 178,181	$ 104,717
Revenue, % change	49.00%		70.00%
Diagnostics [Member]
Segment Reporting Information [Line Items]
Revenue	$ 31,949	34,942	$ 62,270	69,733
Revenue, % change	(9.00%)		(11.00%)
Diagnostics [Member] | Gastrointestinal Assays [Member]
Segment Reporting Information [Line Items]
Revenue	$ 15,666	14,014	$ 31,118	30,060
Revenue, % change	12.00%		4.00%
Diagnostics [Member] | Respiratory Illness Assays [Member]
Segment Reporting Information [Line Items]
Revenue	$ 3,686	10,863	$ 8,492	18,612
Revenue, % change	(66.00%)		(54.00%)
Diagnostics [Member] | Blood Chemistry Assays [Member]
Segment Reporting Information [Line Items]
Revenue	$ 4,358	4,194	$ 8,753	9,142
Revenue, % change	4.00%		(4.00%)
Diagnostics [Member] | Other [Member]
Segment Reporting Information [Line Items]
Revenue	$ 8,239	$ 5,871	$ 13,907	$ 11,919
Revenue, % change	40.00%		17.00%

Revenue Recognition - Additiona

Revenue Recognition - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Disaggregation of Revenue [Line Items]
Revenues	$ 85,264	$ 57,296	$ 178,181	$ 104,717
Royalty income	2,845	1,280	3,705	2,205
Lease Elements [Member] | Product Concentration Risk [Member] | Revenues [Member] | Reagent Rental Arrangements [Member]
Disaggregation of Revenue [Line Items]
Revenues	$ 900	$ 1,125	$ 1,780	$ 2,250

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Fair Value, Assets and Liabilities Measured on Recurring Basis (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Sep. 30, 2020
Derivative Liability, Noncurrent	$ 254	$ 713
Interest Rate Swap [Member]
Derivative Liability, Noncurrent	(254)	(713)
Commitments [Member]
Business Combination, Contingent Consideration, Liability	(18,967)	(20,909)
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Interest Rate Swap [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Commitments [Member]
Business Combination, Contingent Consideration, Liability	0	0
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Interest Rate Swap [Member]
Derivative Liability, Noncurrent	(254)	(713)
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Commitments [Member]
Business Combination, Contingent Consideration, Liability	0	0
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Interest Rate Swap [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Commitments [Member]
Business Combination, Contingent Consideration, Liability	$ (18,967)	$ (20,909)

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Jun. 03, 2019
Interest Rate Swap [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value Measurements [Line Items]
Notional amount of the swaps	$ 50,000
GenePOC
Fair Value Measurements [Line Items]
Contingent consideration liability		$ 27,202
GenePOC | Maximum [Member] | Product Development Milestones [Member]
Fair Value Measurements [Line Items]
Potential milestone payment	14,000
GenePOC | Maximum [Member] | Product Development Milestones [Member] | On Acquisition Date [Member]
Fair Value Measurements [Line Items]
Potential milestone payment	20,000
GenePOC | Maximum [Member] | Financial Performance Targets [Member]
Fair Value Measurements [Line Items]
Potential milestone payment	50,000
GenePOC | Maximum [Member] | Product Development Milestones And Financial Performance Targets [Member]
Fair Value Measurements [Line Items]
Potential milestone payment	64,000
GenePOC | Maximum [Member] | Product Development Milestones And Financial Performance Targets [Member] | On Acquisition Date [Member]
Fair Value Measurements [Line Items]
Potential milestone payment	$ 70,000

Business Combinations - Additio

Business Combinations - Additional Information (Detail) $ in Thousands, ₪ in Millions	Apr. 30, 2020USD ($)	Apr. 30, 2020ILS (₪)	Apr. 30, 2020USD ($)	Mar. 31, 2021USD ($)	Mar. 31, 2020USD ($)	Mar. 31, 2021USD ($)	Mar. 31, 2020USD ($)	Sep. 30, 2020USD ($)
Goodwill				$ 115,296		$ 115,296		$ 114,186
Amortization of identifiable assets				2,142	$ 1,727	4,363	$ 3,449
Exalenz [Member]
Cash payment to acquire business	$ 48,237	₪ 168.6
Goodwill	24,827		$ 24,827
Amortization of identifiable assets				$ 720		$ 1,520
Percentage of Voting Interest				100.00%		100.00%
Business Combination Consideration Transferred	$ 56,305
Net Cash Outlay To Acquire Businesses			$ 47,392

Business Combinations - Summary

Business Combinations - Summary of Business Acquisitions, by Acquisition (Detail) - Exalenz [Member] - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Mar. 31, 2021	Mar. 31, 2021
Net revenues	$ 2,784	$ 5,882
Net loss	$ (947)	$ (1,739)

Business Combinations - Schedul

Business Combinations - Schedule Of Assets Acquired And Liabilities (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Sep. 30, 2020	Apr. 30, 2020
Fair value of assets acquired -
Goodwill	$ 115,296	$ 114,186
Exalenz [Member]
Fair value of assets acquired -
Cash			$ 5,006
Accounts receivable			637
Inventories			4,033
Other current assets			2,676
Property, plant and equipment			528
Goodwill			24,827
Other intangible assets (estimated useful life):
Right-of-use assets			1,311
Deferred tax assets, net			6,744
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets			76,492
Fair value of liabilities assumed -
Accounts payable and accrued expenses			8,008
Long-term lease obligations			1,096
Long-term government grant obligations			10,792
Other non-current liabilities			291
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities			20,187
Total consideration			56,305
Exalenz [Member] | Previously Reported [Member]
Fair value of assets acquired -
Cash			5,006
Accounts receivable			637
Inventories			4,329
Other current assets			851
Property, plant and equipment			544
Goodwill			29,288
Other intangible assets (estimated useful life):
Right-of-use assets			1,358
Deferred tax assets, net			5,566
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets			76,199
Fair value of liabilities assumed -
Accounts payable and accrued expenses			7,757
Long-term lease obligations			1,054
Long-term government grant obligations			10,792
Other non-current liabilities			291
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities			19,894
Total consideration			56,305
Exalenz [Member] | Measurement Period Adjustments [Member]
Fair value of assets acquired -
Inventories			(296)
Other current assets			1,825
Property, plant and equipment			(16)
Goodwill			(4,461)
Other intangible assets (estimated useful life):
Right-of-use assets			(47)
Deferred tax assets, net			1,178
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets			293
Fair value of liabilities assumed -
Accounts payable and accrued expenses			251
Long-term lease obligations			42
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities			293
Exalenz [Member] | Technology-Based Intangible Assets [Member]
Other intangible assets (estimated useful life):
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill			6,120
Exalenz [Member] | Technology-Based Intangible Assets [Member] | Previously Reported [Member]
Other intangible assets (estimated useful life):
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill			5,590
Exalenz [Member] | Technology-Based Intangible Assets [Member] | Measurement Period Adjustments [Member]
Other intangible assets (estimated useful life):
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill			530
Exalenz [Member] | Noncompete Agreements [Member]
Other intangible assets (estimated useful life):
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill			110
Exalenz [Member] | Noncompete Agreements [Member] | Previously Reported [Member]
Other intangible assets (estimated useful life):
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill			120
Exalenz [Member] | Noncompete Agreements [Member] | Measurement Period Adjustments [Member]
Other intangible assets (estimated useful life):
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill			(10)
Exalenz [Member] | Trade Names [Member]
Other intangible assets (estimated useful life):
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill			3,860
Exalenz [Member] | Trade Names [Member] | Previously Reported [Member]
Other intangible assets (estimated useful life):
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill			3,540
Exalenz [Member] | Trade Names [Member] | Measurement Period Adjustments [Member]
Other intangible assets (estimated useful life):
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill			320
Exalenz [Member] | Customer Relationships [Member]
Other intangible assets (estimated useful life):
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill			20,640
Exalenz [Member] | Customer Relationships [Member] | Previously Reported [Member]
Other intangible assets (estimated useful life):
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill			19,370
Exalenz [Member] | Customer Relationships [Member] | Measurement Period Adjustments [Member]
Other intangible assets (estimated useful life):
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill			$ 1,270

Business Combinations - Sched_2

Business Combinations - Schedule Of Assets Acquired And Liabilities (Parenthetical) (Detail) $ in Thousands	Apr. 30, 2020USD ($)
Acquired Finite-Lived Intangible Assets [Line Items]
Paid to the sellers to payoff debt	$ 8,068
Technology-Based Intangible Assets [Member] | Exalenz [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	15 years
Noncompete Agreements [Member] | Exalenz [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	5 years
Trade Names [Member] | Exalenz [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	10 years
Customer Relationships [Member] | Exalenz [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	10 years

Business Combinations - Consoli

Business Combinations - Consolidated Pro Forma Results Of The Combined Entities (Detail) - Exalenz [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Business Acquisition, Pro Forma Information [Abstract]
Net revenues	$ 85,264	$ 60,701	$ 178,181	$ 111,895
Net earnings	$ 26,302	$ 8,064	$ 53,081	$ 9,246

Business Combinations - Busines

Business Combinations - Business Acquisition, Pro Forma Adjustments (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Adjustments to net revenues
Exalenz pre-acquisition net revenues	$ 0	$ 3,405	$ 0	$ 7,178
Adjustments to net earnings
Exalenz pre-acquisition net loss	0	(752)	0	(1,504)
Pro forma adjustments:
Expenses related to non-continuing personnel, locations or activities	0	490	0	591
Incremental depreciation and amortization	0	(911)	0	(1,824)
Incremental interest costs	0	(381)	0	(772)
Tax effects of pro forma adjustments	0	259	0	569
Total adjustments to net earnings	$ 0	$ (1,295)	$ 0	$ (2,940)

Cash and Cash Equivalents - Com

Cash and Cash Equivalents - Components of Cash and Cash Equivalents (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Sep. 30, 2020
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 63,374	$ 53,514
Institutional Money Market Funds [Member]
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	1,017	1,017
Cash on hand, unrestricted [Member]
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 62,357	$ 52,497

Inventories, Net - Components o

Inventories, Net - Components of Inventories (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Sep. 30, 2020
Inventory [Line Items]
Raw materials	$ 18,706	$ 11,966
Work-in-process	22,987	19,477
Total	72,534	61,264
Instruments [Member]
Inventory [Line Items]
Finished goods	1,933	1,594
Kits and Reagents [Member]
Inventory [Line Items]
Finished goods	$ 28,908	$ 28,227

Leasing Arrangements - Schedule

Leasing Arrangements - Schedule of Condensed Income Statement Of Operation (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Condensed Income Statements, Captions [Line Items]
Right-of-use assets, net obtained in exchange for operating lease liabilities	$ 612	$ 222	$ 692	$ 222
Lease costs within cost of sales
Condensed Income Statements, Captions [Line Items]
Operating lease cost	198	130	356	259
Lease costs within operating expenses
Condensed Income Statements, Captions [Line Items]
Operating lease cost	$ 387	$ 292	$ 761	$ 559

Leasing Arrangements - Schedu_2

Leasing Arrangements - Schedule of Weighted Average Remaining Lease Term and Discount Rate (Detail)	Mar. 31, 2021	Sep. 30, 2020
Weighted Average Remaining Lease Term And Weighted Average Discount rate Used To Measure Operating Lease [Abstract]
Weighted average remaining lease term	3 years 9 months 18 days	4 years 2 months 12 days
Average discount rate	3.40%	3.70%

Leasing Arrangements - Schedu_3

Leasing Arrangements - Schedule of maturities of lease liabilities (Detail) $ in Thousands	Mar. 31, 2021USD ($)
Operating lease liabilities
2021 (represents remainder of fiscal year)	$ 1,108
2022	2,016
2023	1,482
2024	1,108
2025	806
Thereafter	331
Total lease payments	6,851
Less amount of lease payments representing interest	(404)
Total present value of lease payments	$ 6,447

Leasing Arrangements - Schedu_4

Leasing Arrangements - Schedule Of Supplemental Cash Flow Information Related To The CompanyS Operating Lease Liabilities (Detail) - USD ($) $ in Thousands	6 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 1,072	$ 778

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets, Net - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Amortization of Intangible Assets	$ 2,142	$ 1,727	$ 4,363	$ 3,449
2021	4,210		4,210
2022	8,000		8,000
2023	7,975		7,975
2024	7,975		7,975
2025	7,950		7,950
2026	7,300		7,300
Increase decrease in goodwill during the period			1,110
Exalenz [Member]
Amortization of Intangible Assets	$ 720		1,520
Diagnostics [Member]
Increase decrease in goodwill foreign currency translation adjustment			67
Diagnostics [Member] | Exalenz [Member]
Increase decrease in goodwill acquisition measurement period adjustment			361
Life Science [Member]
Increase decrease in goodwill foreign currency translation adjustment			$ 682

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets, Net - Summary of Acquired Intangible Assets Subject to Amortization (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Sep. 30, 2020
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$ 127,225	$ 126,779
Accumulated Amortization	48,391	43,582
Manufacturing Technologies, Core Products and Cell Lines [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	62,446	62,363
Accumulated Amortization	20,756	18,750
Tradenames, Licenses and Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	18,524	18,425
Accumulated Amortization	8,813	7,801
Customer Lists, Customer Relationships, and Supply Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	45,287	45,071
Accumulated Amortization	17,944	16,210
Government Grants [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	858	810
Accumulated Amortization	858	810
Non-Compete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	110	110
Accumulated Amortization	$ 20	$ 11

Bank Credit Arrangements - Addi

Bank Credit Arrangements - Additional Information (Detail) - USD ($) $ in Thousands	May 24, 2019	Feb. 28, 2021	Dec. 31, 2020	Sep. 30, 2020	Jan. 31, 2020	Mar. 31, 2021	Mar. 31, 2020	Feb. 19, 2020	Dec. 31, 2019	Mar. 22, 2016
Debt Instrument [Line Items]
Line of credit facility borrowing Capacity								$ 160,000
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Debt instrument effective interest rate			2.60%			2.57%	4.04%		4.15%
Line of credit facility borrowing Capacity	$ 125,000
Draws on credit facility				$ 68,824		$ 50,000
Expiration of credit facility	May 2024
Proceeds from Lines of Credit						$ 125,824
Debt instrument principal repayment		$ 8,824	$ 10,000	$ 30,000	$ 27,000
Five - Year Term Loan [Member] | Magellan [Member]
Debt Instrument [Line Items]
Long-term Debt										$ 60,000
Long-term Debt, Term										5 years

Contingent Obligations and No_3

Contingent Obligations and Non-Current Liabilities - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Sep. 30, 2020
Potential Future Severance Indemnity [Member]
Liability for potential severance indemnity	$ 853	$ 814
Former Chief Executive Officer [Member]
Post employment benefit obligations	1,748	1,840
Exalenz [Member] | Long Term Government Grant Obligations [Member]
Long term government grant obligations assumed payable	$ 11,145	$ 11,124
Percentage of revenue generated to be applied towards repayment of grant obligations	3.00%
Maximum [Member] | London Interbank Offered Rate (LIBOR) [Member] | Exalenz [Member] | Long Term Government Grant Obligations [Member]
Long term debt stated rate of interest	6.60%
Minimum [Member] | London Interbank Offered Rate (LIBOR) [Member] | Exalenz [Member] | Long Term Government Grant Obligations [Member]
Long term debt stated rate of interest	0.58%

Contingent Obligations and No_4

Contingent Obligations and Non-Current Liabilities - Schedule of Government Grant Obligations Reflected in Condensed Consolidated Balance Sheet (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Sep. 30, 2020
Contingent Obligations and NonCurrent Liabilities Disclosure [Abstract]
Current liabilities	$ 608	$ 600
Non-current liabilities	$ 10,537	$ 10,524

National Institutes of Health_2

National Institutes of Health Contracts - Additional information (Detail) - USD ($) $ in Thousands	Feb. 01, 2021	Mar. 31, 2021	Dec. 31, 2020
Health contracts relating to research and development [Line Items]
Grant Receipts Upon Milestone Achievement	$ 5,500
Grant Contract Lease Term	12 months
National Institute Of Health [Member] | Reimbursement Of Research And Development Expenditure Accrued [Member]
Health contracts relating to research and development [Line Items]
Reimbursement of research and development expenditure		$ 1,000	$ 200

Reportable Segments and Major C

Reportable Segments and Major Concentration Data - Consolidated Net Revenues (Detail)	3 Months Ended		6 Months Ended		12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020	Sep. 30, 2020
Customer A [Member] | Revenues [Member] | Diagnostics [Member] | Segment Level [Member]
Entity Wide Portfolio Carrying Amount, Major Customer [Line Items]
Concentration percentage	10.00%	9.00%	11.00%	11.00%
Customer B [Member] | Revenues [Member] | Diagnostics [Member] | Segment Level [Member]
Entity Wide Portfolio Carrying Amount, Major Customer [Line Items]
Concentration percentage	10.00%	13.00%	10.00%	14.00%
Customer C [Member] | Revenues [Member] | Diagnostics [Member] | Segment Level [Member]
Entity Wide Portfolio Carrying Amount, Major Customer [Line Items]
Concentration percentage	11.00%	5.00%	11.00%	5.00%
Customer D [Member] | Revenues [Member] | Life Science [Member] | Segment Level [Member]
Entity Wide Portfolio Carrying Amount, Major Customer [Line Items]
Concentration percentage	9.00%	13.00%	6.00%	11.00%
Customer D [Member] | Customer Concentration Risk [Member] | Life Science [Member] | Consolidated Level [Member]
Entity Wide Portfolio Carrying Amount, Major Customer [Line Items]
Concentration percentage			10.00%		8.00%
Customer E [Member] | Revenues [Member] | Life Science [Member] | Segment Level [Member]
Entity Wide Portfolio Carrying Amount, Major Customer [Line Items]
Concentration percentage	9.00%	5.00%	14.00%	4.00%
Customer E [Member] | Customer Concentration Risk [Member] | Life Science [Member] | Consolidated Level [Member]
Entity Wide Portfolio Carrying Amount, Major Customer [Line Items]
Concentration percentage			3.00%		15.00%

Reportable Segment and Major _3

Reportable Segment and Major Customers Information - Additional Information (Detail)	3 Months Ended		6 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
COVID-19 Revenue [Member] | Operating Segments [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage	37.00%		41.00%
Life Science [Member] | COVID-19 Revenue [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage	58.00%		64.00%
One Single Customer [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage	10.00%	10.00%	10.00%	10.00%
Individual Diagnostics or Life Science Segment Customers [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage	10.00%	10.00%	10.00%	10.00%
Life Science Segment Ten Largest Customer [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage	48.00%		30.00%

Reportable Segment and Major _4

Reportable Segment and Major Customers Information - Reportable Segment Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020	Sep. 30, 2020
Segment Reporting Information [Line Items]
Net revenues	$ 85,264	$ 57,296	$ 178,181	$ 104,717
Operating income (loss)	34,201	11,791	68,865	17,185
Goodwill	115,296		115,296		$ 114,186
Other intangible assets	78,834		78,834		83,197
Total assets	439,169		439,169		405,261
Restructuring and litigation costs	1,030	685	2,257	1,055
Corporate [Member]
Segment Reporting Information [Line Items]
Operating income (loss)	(4,325)	(2,896)	(8,288)	(4,983)
Eliminations [Member]
Segment Reporting Information [Line Items]
Operating income (loss)	16	27	28	39
Total assets	(49)		(49)		(34)
Net revenues	(207)	(136)	(294)	(298)
Operating Segments [Member]
Segment Reporting Information [Line Items]
Operating income (loss)	38,526	14,687	77,153	22,168
Operating Segments [Member] | Diagnostics [Member]
Segment Reporting Information [Line Items]
Net revenues	31,949	34,942	62,270	69,733
Operating income (loss)	2,421	4,729	1,239	9,870
Goodwill	95,283		95,283		94,855
Other intangible assets	78,832		78,832		83,179
Total assets	313,271		313,271		306,812
Net revenues	116	81	185	178
Operating Segments [Member] | Life Science [Member]
Segment Reporting Information [Line Items]
Net revenues	53,315	22,354	115,911	34,984
Operating income (loss)	36,089	9,931	75,886	12,259
Goodwill	20,013		20,013		19,331
Other intangible assets	2		2		18
Total assets	125,947		125,947		$ 98,483
Net revenues	$ 91	$ 55	$ 109	$ 120

Reportable Segment and Major _5

Reportable Segment and Major Customers Information - Pre-tax Earnings Table (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Corporate operating expenses	$ (4,325)	$ (2,896)	$ (8,288)	$ (4,983)
Interest income	6	23	15	134
Interest expense	(472)	(532)	(1,006)	(1,299)
Other, net	(883)	1,365	(1,574)	653
EARNINGS BEFORE INCOME TAXES	33,052	12,647	67,300	16,673
RADx initiative grant income	200		1,000
Operating income	34,201	11,791	68,865	17,185
Operating Segments [Member]
Operating income	38,526	14,687	77,153	22,168
Operating Segments [Member] | Diagnostics [Member]
Operating income	2,421	4,729	1,239	9,870
Operating Segments [Member] | Life Science [Member]
Operating income	36,089	9,931	75,886	12,259
Eliminations [Member]
Operating income	$ 16	$ 27	$ 28	$ 39

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail)	3 Months Ended		6 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Income Taxes Disclosure [Line Items]
Effective income tax rate continuing operations	20.00%	26.00%	21.00%	27.00%

Litigation Matters - Additional

Litigation Matters - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Litigation costs [Abstract]
Litigation costs	$ 1,030	$ 735	$ 2,257	$ 1,055
DOJ Subpoena [Member]
Litigation costs [Abstract]
Litigation filing date			April 17, 2018
Litigation costs	$ 1,030	$ 725	$ 2,257	$ 1,005